465 related articles for article (PubMed ID: 8646356)
1. Effective therapy: repeat limb perfusion for recurrent melanoma.
Krementz ET
J Am Coll Surg; 1996 Jun; 182(6):547-8. PubMed ID: 8646356
[No Abstract] [Full Text] [Related]
2. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
3. [Clinical results of extremity perfusion in malignant melanoma].
Huber R; Stützer H; Krüger I
Zentralbl Chir; 1996; 121(3):234-42. PubMed ID: 8867351
[TBL] [Abstract][Full Text] [Related]
4. Isolated limb perfusion for melanoma.
Kroon BB; Noorda EM; Vrouenraets BC; Nieweg OE
J Surg Oncol; 2002 Apr; 79(4):252-5. PubMed ID: 11920783
[No Abstract] [Full Text] [Related]
5. Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases.
Pace M; Gattai R; Mascitelli EM; Millanta L
J Surg Oncol; 2011 Dec; 104(7):718-23. PubMed ID: 21721008
[TBL] [Abstract][Full Text] [Related]
6. [Regional cytostatic perfusion of the extremities in patients with malignant melanoma and soft tissue sarcoma--therapeutic applications and results].
Eichfeld U; Gläser A; Schneider G; Kraus J; Pauer HJ; Schwarz I
Zentralbl Chir; 1993; 118(2):63-8. PubMed ID: 7682024
[TBL] [Abstract][Full Text] [Related]
7. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
8. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.
Lejeune FJ; Eggermont AM
J Clin Oncol; 2007 Apr; 25(11):1449-50; author reply 1450-1. PubMed ID: 17416870
[No Abstract] [Full Text] [Related]
9. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Kettelhack C; Hohenberger P; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
11. [Value of regional lymph node excision for prognosis of advanced malignant melanoma treated by perfusion of the extremity].
Huber R; Krüger I; Stützer H
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():118-21. PubMed ID: 9101808
[TBL] [Abstract][Full Text] [Related]
12. [Preventive lymph node excision in the treatment concept of melanoma of the extremities].
Binder J; Henneking K
Zentralbl Chir; 1996; 121(6):474-7. PubMed ID: 8767334
[TBL] [Abstract][Full Text] [Related]
13. Isolated limb infusion for melanoma: a less morbid alternative to hyperthermic isolated limb perfusion in the US.
Santillan AA; Zager JS
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1033-7. PubMed ID: 20078252
[No Abstract] [Full Text] [Related]
14. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma.
Lindnér P; Doubrovsky A; Kam PC; Thompson JF
Ann Surg Oncol; 2002 Mar; 9(2):127-36. PubMed ID: 11888868
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic hyperthermic limb perfusion in stage I melanoma.
Krige JE; King HS; Strover RM
Eur J Surg Oncol; 1988 Aug; 14(4):321-6. PubMed ID: 3044834
[TBL] [Abstract][Full Text] [Related]
16. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities--long-term follow-up of a randomised trial.
Olofsson Bagge R; Mattsson J; Hafström L
Int J Hyperthermia; 2014 Aug; 30(5):295-8. PubMed ID: 25144818
[TBL] [Abstract][Full Text] [Related]
17. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
18. The use of isolated limb perfusion to manage recurrent malignant melanoma.
Ma D; Ariyan S
Clin Plast Surg; 2000 Jul; 27(3):441-50, ix. PubMed ID: 10941564
[TBL] [Abstract][Full Text] [Related]
19. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
[TBL] [Abstract][Full Text] [Related]
20. [Regional isolated perfusion: also applicable in elderly patients].
Noorda EM; Vrouenraets BC; Nieweg OE; Kroon BB
Ned Tijdschr Geneeskd; 2003 Mar; 147(12):529-33. PubMed ID: 12693077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]